Plain-English translation of NCT07201376 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging device that uses fluorescent light technology to help doctors better identify skin cancer and map out exactly where cancerous tissue ends during surgery. The study involves applying Ameluz, an FDA-approved medication, to your skin and then using a special imaging camera to take pictures. Researchers want to see if this imaging tool can help doctors more accurately distinguish between benign skin growths and skin cancer.
Currently, doctors rely on visual inspection and biopsy to diagnose skin cancer and determine how much tissue to remove during surgery. This imaging technology could give doctors a clearer, real-time picture of cancerous tissue, potentially leading to more precise surgery and better outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, a healthcare provider will apply the medication Ameluz to your skin lesion. After waiting a short period for the medication to be absorbed, you will undergo imaging using the special tissue oxygen imager—a non-invasive procedure where a camera takes fluorescent pictures of the area. The entire visit is typically one time, and the imaging is done right before or during your scheduled surgery to remove the lesion.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States